Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 9
2003 9
2004 27
2005 38
2006 37
2007 48
2008 76
2009 107
2010 86
2011 102
2012 133
2013 99
2014 106
2015 113
2016 142
2017 119
2018 138
2019 154
2020 172
2021 193
2022 187
2023 148
2024 147
2025 201
2026 75

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,011 results

Results by year

Filters applied: . Clear all
Page 1
Impact of BCG failure patterns on efficacy of intravesical gemcitabine/docetaxel in high-risk non-muscle-invasive bladder cancer.
Scilipoti P, Zaurito P, Longoni M, Tremolada G, Occhi A, Dutto D, Katzendorn O, Krajewski W, Laukhtina E, Elena JLR, Aranda J, Contieri R, Hurle R, Subiela JD, Lucena PE, Fernández A, Marcq G, Szostek A, Pichler R, Álvarez-Maestro M, Bazán AA, Klatte T, du Biest AM, Ferrando V, Buisan O, López AV, Soria F, Pradere B, D Andrea D, Shariat SF, Colecchia M, Montorsi F, Briganti A, Gontero P, Xylinas E, Moschini M; European Association of Urology – Young Academic Urologists (EAU‐YAU), Urothelial Carcinoma Working Group and the EuroGemDoce Study Group Collaborators. Scilipoti P, et al. Among authors: montorsi f. BJU Int. 2026 May;137(5):821-828. doi: 10.1111/bju.70182. Epub 2026 Feb 25. BJU Int. 2026. PMID: 41742675
Cancer-specific mortality differences between radical prostatectomy and radiotherapy after biochemical recurrence: analysis of a health system-wide cohort.
Silvani C, Santangelo A, Stephens A, Considine J, Msska A, Perry M, Sood A, Catanzaro M, Briganti A, Salonia A, Montorsi F, Nicolai N, Montanari E, Rogers C, Abdollah F. Silvani C, et al. Among authors: montorsi f. World J Urol. 2026 Apr 15;44(1):309. doi: 10.1007/s00345-026-06387-0. World J Urol. 2026. PMID: 41984246 No abstract available.
The impact of age in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-Guérin.
Scilipoti P, Zaurito P, Longoni M, Occhi A, de Angelis M, Disabato N, Tremolada G, Barracco S, Ślusarczyk A, Soria F, Krajewski W, D'Andrea D, Mari A, Giudice FD, Pichler R, Subiela JD, Marcq G, Gallioli A, Afferi L, Mastroianni R, Simone G, Albisinni S, Mertens LS, Laukhtina E, Oberneder K, Elena JLR, Aranda J, Puentedura AL, Velasco JC, Contieri R, Hurle R, Mori K, Radziszewski P, Shariat SF, Gontero P, Rouprêt M, Pradere B, Montorsi F, Briganti A, Moschini M; European Association of Urology - Young Academic Urologists (EAU-YAU), Urothelial carcinoma working group. Scilipoti P, et al. Among authors: montorsi f. Urol Oncol. 2026 Apr 11:111085. doi: 10.1016/j.urolonc.2026.111085. Online ahead of print. Urol Oncol. 2026. PMID: 41967989
Anatomical distribution and predictors of lymph node metastasis in robot-assisted radical nephroureterectomy for upper tract urothelial carcinoma: a multicenter study by the Junior ERUS/YAU Robotic Surgery Working Group.
Di Maida F, Lambertini L, Bravi CA, De Groote R, Piramide F, Turri F, Wenzel M, Sharma G, Würnschimmel C, Lambert E, Dell'Oglio P, Moschovas MC, Campi R, Grosso AA, Liakos N, Mayr R, Darlington D, Eraky A, Paciotti M, Sorce G, Tappero S, Mottaran A, Larcher A, Montorsi F, Briganti A, Crisan N, Mottrie A, Minervini A, Breda A, Andras I. Di Maida F, et al. Among authors: montorsi f. World J Urol. 2026 Apr 11;44(1):292. doi: 10.1007/s00345-026-06371-8. World J Urol. 2026. PMID: 41964762 No abstract available.
Risk stratification of Ta high-grade non-muscle-invasive bladder cancer: Insights from a multicenter cohort study.
Zaurito P, Scilipoti P, Longoni M, de Angelis M, Ślusarczyk A, Viti A, Santangelo A, Tremolada G, Soria F, Pradere B, Krajewski W, D'Andrea D, Mari A, Giudice FD, Pichler R, Subiela JD, Marcq G, Gallioli A, Afferi L, Mastroianni R, Simone G, Albisinni S, Mertens LS, Laukhtina E, Oberneder K, Elena JLR, Aranda J, Puentedura AL, Velasco JC, Contieri R, Hurle R, Mori K, Radziszewski P, Shariat SF, Gontero P, Rouprêt M, Montorsi F, Salonia A, Briganti A, Moschini M; European Association of Urology - Young Academic Urologists (EAU-YAU), Urothelial carcinoma working group. Zaurito P, et al. Among authors: montorsi f. Urol Oncol. 2026 Apr 2:111089. doi: 10.1016/j.urolonc.2026.111089. Online ahead of print. Urol Oncol. 2026. PMID: 41934021
Neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by adjuvant pembrolizumab, in patients with muscle-invasive bladder cancer (SURE-02): a single-arm, phase 2 study.
Necchi A, Maiorano BA, de Jong JJ, Proudfoot JA, Basile G, Cigliola A, Mercinelli C, Tateo V, Piacentini M, Pastorino G, Latini G, Tomasi E, Davicioni E, Moschini M, Brembilla G, Colecchia M, de Cobelli F, Briganti A, Ross JS, Pavlick DC, Montorsi F. Necchi A, et al. Among authors: montorsi f. Lancet Oncol. 2026 Apr;27(4):442-451. doi: 10.1016/S1470-2045(26)00050-1. Epub 2026 Feb 27. Lancet Oncol. 2026. PMID: 41771275 Clinical Trial.
Optimizing oncological outcomes in high-grade non-muscle invasive bladder cancer: The impact of a surgeon-led treatment pathway.
Scilipoti P, Rosiello G, Santangelo A, Viti A, Longoni M, Occhi A, Brancaccio M, Tremolada G, Folcia A, Zaurito P, de Angelis M, Karakiewicz PI, Mottrie A, Lucianò R, Colecchia M, Salonia A, Briganti A, Moschini M, Montorsi F. Scilipoti P, et al. Among authors: montorsi f. Urol Oncol. 2026 Apr;44(4):111007. doi: 10.1016/j.urolonc.2026.111007. Epub 2026 Feb 13. Urol Oncol. 2026. PMID: 41689869
2,011 results